Abstract
Summary
LPI (LP Information)' newest research report, the “Phenylketonuria Medication Industry Forecast” looks at past sales and reviews total world Phenylketonuria Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Phenylketonuria Medication sales for 2023 through 2029. With Phenylketonuria Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Phenylketonuria Medication industry.
This Insight Report provides a comprehensive analysis of the global Phenylketonuria Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phenylketonuria Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Phenylketonuria Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phenylketonuria Medication and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phenylketonuria Medication.
The global Phenylketonuria Medication market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Phenylketonuria Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Phenylketonuria Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Phenylketonuria Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Phenylketonuria Medication players cover Biomarin, Vitaflo, Mead Johnson, Nutricia, Abbott, Dr. Schär, Prominmetabolics, Cambrooke and Juvela, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Phenylketonuria Medication market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Kuvan
Palynziq
Others
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biomarin
Vitaflo
Mead Johnson
Nutricia
Abbott
Dr. Schär
Prominmetabolics
Cambrooke
Juvela
Firstplay Dietary
PKU Perspectives
This Insight Report provides a comprehensive analysis of the global Phenylketonuria Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phenylketonuria Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Phenylketonuria Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phenylketonuria Medication and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phenylketonuria Medication.
The global Phenylketonuria Medication market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Phenylketonuria Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Phenylketonuria Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Phenylketonuria Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Phenylketonuria Medication players cover Biomarin, Vitaflo, Mead Johnson, Nutricia, Abbott, Dr. Schär, Prominmetabolics, Cambrooke and Juvela, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Phenylketonuria Medication market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Kuvan
Palynziq
Others
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biomarin
Vitaflo
Mead Johnson
Nutricia
Abbott
Dr. Schär
Prominmetabolics
Cambrooke
Juvela
Firstplay Dietary
PKU Perspectives
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Phenylketonuria Medication Market Size 2018-2029
2.1.2 Phenylketonuria Medication Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Phenylketonuria Medication Segment by Type
2.2.1 Kuvan
2.2.2 Palynziq
2.2.3 Others
2.3 Phenylketonuria Medication Market Size by Type
2.3.1 Phenylketonuria Medication Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Phenylketonuria Medication Market Size Market Share by Type (2018-2023)
2.4 Phenylketonuria Medication Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Phenylketonuria Medication Market Size by Application
2.5.1 Phenylketonuria Medication Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Phenylketonuria Medication Market Size Market Share by Application (2018-2023)
3 Phenylketonuria Medication Market Size by Player
3.1 Phenylketonuria Medication Market Size Market Share by Players
3.1.1 Global Phenylketonuria Medication Revenue by Players (2018-2023)
3.1.2 Global Phenylketonuria Medication Revenue Market Share by Players (2018-2023)
3.2 Global Phenylketonuria Medication Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Phenylketonuria Medication by Regions
4.1 Phenylketonuria Medication Market Size by Regions (2018-2023)
4.2 Americas Phenylketonuria Medication Market Size Growth (2018-2023)
4.3 APAC Phenylketonuria Medication Market Size Growth (2018-2023)
4.4 Europe Phenylketonuria Medication Market Size Growth (2018-2023)
4.5 Middle East & Africa Phenylketonuria Medication Market Size Growth (2018-2023)
5 Americas
5.1 Americas Phenylketonuria Medication Market Size by Country (2018-2023)
5.2 Americas Phenylketonuria Medication Market Size by Type (2018-2023)
5.3 Americas Phenylketonuria Medication Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Phenylketonuria Medication Market Size by Region (2018-2023)
6.2 APAC Phenylketonuria Medication Market Size by Type (2018-2023)
6.3 APAC Phenylketonuria Medication Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Phenylketonuria Medication by Country (2018-2023)
7.2 Europe Phenylketonuria Medication Market Size by Type (2018-2023)
7.3 Europe Phenylketonuria Medication Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Phenylketonuria Medication by Region (2018-2023)
8.2 Middle East & Africa Phenylketonuria Medication Market Size by Type (2018-2023)
8.3 Middle East & Africa Phenylketonuria Medication Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Phenylketonuria Medication Market Forecast
10.1 Global Phenylketonuria Medication Forecast by Regions (2024-2029)
10.1.1 Global Phenylketonuria Medication Forecast by Regions (2024-2029)
10.1.2 Americas Phenylketonuria Medication Forecast
10.1.3 APAC Phenylketonuria Medication Forecast
10.1.4 Europe Phenylketonuria Medication Forecast
10.1.5 Middle East & Africa Phenylketonuria Medication Forecast
10.2 Americas Phenylketonuria Medication Forecast by Country (2024-2029)
10.2.1 United States Phenylketonuria Medication Market Forecast
10.2.2 Canada Phenylketonuria Medication Market Forecast
10.2.3 Mexico Phenylketonuria Medication Market Forecast
10.2.4 Brazil Phenylketonuria Medication Market Forecast
10.3 APAC Phenylketonuria Medication Forecast by Region (2024-2029)
10.3.1 China Phenylketonuria Medication Market Forecast
10.3.2 Japan Phenylketonuria Medication Market Forecast
10.3.3 Korea Phenylketonuria Medication Market Forecast
10.3.4 Southeast Asia Phenylketonuria Medication Market Forecast
10.3.5 India Phenylketonuria Medication Market Forecast
10.3.6 Australia Phenylketonuria Medication Market Forecast
10.4 Europe Phenylketonuria Medication Forecast by Country (2024-2029)
10.4.1 Germany Phenylketonuria Medication Market Forecast
10.4.2 France Phenylketonuria Medication Market Forecast
10.4.3 UK Phenylketonuria Medication Market Forecast
10.4.4 Italy Phenylketonuria Medication Market Forecast
10.4.5 Russia Phenylketonuria Medication Market Forecast
10.5 Middle East & Africa Phenylketonuria Medication Forecast by Region (2024-2029)
10.5.1 Egypt Phenylketonuria Medication Market Forecast
10.5.2 South Africa Phenylketonuria Medication Market Forecast
10.5.3 Israel Phenylketonuria Medication Market Forecast
10.5.4 Turkey Phenylketonuria Medication Market Forecast
10.5.5 GCC Countries Phenylketonuria Medication Market Forecast
10.6 Global Phenylketonuria Medication Forecast by Type (2024-2029)
10.7 Global Phenylketonuria Medication Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Biomarin
11.1.1 Biomarin Company Information
11.1.2 Biomarin Phenylketonuria Medication Product Offered
11.1.3 Biomarin Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Biomarin Main Business Overview
11.1.5 Biomarin Latest Developments
11.2 Vitaflo
11.2.1 Vitaflo Company Information
11.2.2 Vitaflo Phenylketonuria Medication Product Offered
11.2.3 Vitaflo Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Vitaflo Main Business Overview
11.2.5 Vitaflo Latest Developments
11.3 Mead Johnson
11.3.1 Mead Johnson Company Information
11.3.2 Mead Johnson Phenylketonuria Medication Product Offered
11.3.3 Mead Johnson Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Mead Johnson Main Business Overview
11.3.5 Mead Johnson Latest Developments
11.4 Nutricia
11.4.1 Nutricia Company Information
11.4.2 Nutricia Phenylketonuria Medication Product Offered
11.4.3 Nutricia Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Nutricia Main Business Overview
11.4.5 Nutricia Latest Developments
11.5 Abbott
11.5.1 Abbott Company Information
11.5.2 Abbott Phenylketonuria Medication Product Offered
11.5.3 Abbott Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Abbott Main Business Overview
11.5.5 Abbott Latest Developments
11.6 Dr. Schär
11.6.1 Dr. Schär Company Information
11.6.2 Dr. Schär Phenylketonuria Medication Product Offered
11.6.3 Dr. Schär Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Dr. Schär Main Business Overview
11.6.5 Dr. Schär Latest Developments
11.7 Prominmetabolics
11.7.1 Prominmetabolics Company Information
11.7.2 Prominmetabolics Phenylketonuria Medication Product Offered
11.7.3 Prominmetabolics Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Prominmetabolics Main Business Overview
11.7.5 Prominmetabolics Latest Developments
11.8 Cambrooke
11.8.1 Cambrooke Company Information
11.8.2 Cambrooke Phenylketonuria Medication Product Offered
11.8.3 Cambrooke Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Cambrooke Main Business Overview
11.8.5 Cambrooke Latest Developments
11.9 Juvela
11.9.1 Juvela Company Information
11.9.2 Juvela Phenylketonuria Medication Product Offered
11.9.3 Juvela Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Juvela Main Business Overview
11.9.5 Juvela Latest Developments
11.10 Firstplay Dietary
11.10.1 Firstplay Dietary Company Information
11.10.2 Firstplay Dietary Phenylketonuria Medication Product Offered
11.10.3 Firstplay Dietary Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Firstplay Dietary Main Business Overview
11.10.5 Firstplay Dietary Latest Developments
11.11 PKU Perspectives
11.11.1 PKU Perspectives Company Information
11.11.2 PKU Perspectives Phenylketonuria Medication Product Offered
11.11.3 PKU Perspectives Phenylketonuria Medication Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 PKU Perspectives Main Business Overview
11.11.5 PKU Perspectives Latest Developments
12 Research Findings and Conclusion